Paediatrics

Prevenar 13® (Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)) is estimated to cover 73-100% (depending on the country) of serotypes causing invasive pneumococcal disease (IPD) in children less than 5 years of age.

In this age group, serotypes 1, 3, 5, 6A, 7F, and 19A account for 15.6% to 59.7% of invasive disease, depending on the country, the time period studied, and the use of Prevenar.

• Acute otitis media (AOM) is a common childhood disease with different aetiologies.
• Bacteria can be responsible for 60-70% of clinical episodes of AOM. Streptococcus pneumoniae is one of the most common causes of bacterial AOM worldwide.
• Prevenar 13 is estimated to cover over 90% of serotypes causing antibiotic-resistant IPD.

Adults

Prevenar 13 adult is indicated for IPD, a serious form of pneumococcal infection with high incidence and significant mortality. This includes bacteremic pneumonia and meningitis, two of the most common manifestations in adults:

• The incidence of IPD increases with age from 50 years and underlying co-morbidities (chronic cardiovascular disease, chronic pulmonary disease including asthma, renal disorders, diabetes mellitus, and chronic liver disease including alcoholic liver disease).
• Bacteraemic pneumonia, bacteraemia without a focus, and meningitis are the most common manifestations of IPD in adults aged 50 years or older.
• Approximately 80 % of IPD in adults is bacteremic pneumonia

From 2008-2010, the serotypes included in Prevenar 13 are responsible for 58% of invasive pneumococcal disease in adults (aged 65 years and above) in England and Wales. Prevenar 13 is expected to provide coverage against 7 out of the 10 most common serotypes causing invasive pneumococcal disease in adults in England and Wales.

Summary of Product Characteristics can be found on electronic Medicines Compendium (eMC) click here to view.

Patient information Leaflet can be found on electronic Medicines Compendium (eMC) click here to view and download.